Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction

Cover Page

Cite item

Full Text

Abstract

Aim : to evaluate effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction. Methods : 30 patients admitted to the clinic for an episode of acute heart failure (AHF) II-IV class NYHA and decreased ejection fraction ≤40% (83.3% of men, mean age 66.0 [58.0-76.0] years) were included into the open study. Patients received the first dose of the study drug no later than 6 hours before discharge from the hospital. The period of active treatment was 26 weeks. At week 12 and 26, the number of patients receiving the target dose of 400 mg/day, as well as the dynamics of symptoms and severity of heart failure (HF) were evaluated. During the entire period of the study, safety parameters were investigated in all patients. Results . 70% of patients (n=21) received the target dose by week 2 77,8% (n=21) received the target dose of 200 mg 2 times a day at week 26. The positive effect in the dynamics of symptoms, as well as the severity of HF in the vast majority of patients were observed, a significant reduction in the severity of the main symptoms of HF was achieved, patients moved to a lower class of HF. 3 patients dropped out due to adverse events (1) and serious adverse events (2). 27 (90%) patients completed the program in accordance with the Protocol. Conclusion . Sacubitril/valsartanis is well tolerated, effective and safety drug in patients with CHF and a low ejection fraction.

About the authors

Z. D. Kobalava

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Email: tolkachevav@mail.ru
Moscow, Russian Federation

S. A. Galochkin

Peoples’ Friendship University of Russia (RUDN University)

Email: tolkachevav@mail.ru
Moscow, Russian Federation

V. V. Tolkacheva

Peoples’ Friendship University of Russia (RUDN University)

Email: tolkachevav@mail.ru
Moscow, Russian Federation

N. Kh. Bagmanova

Peoples’ Friendship University of Russia (RUDN University)

Email: tolkachevav@mail.ru
Moscow, Russian Federation

References

  1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, et al. ESC Committee for Practice Guidelines. ES Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
  2. Christ M, Stork S, Dorr M, Heppner HJ, Muller C, Wachter R, Riemer U, Trend HF Germany Project. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail. 2016;18:1009–18.
  3. Maggioni AP, Anker SD, Dahlstrom U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173–84.
  4. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalisation for heart failure. Nat Rev Cardiol. 2015;12:220–9.
  5. Mareev V.Y., Fomin I.V., Ageev F.T., et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018; 58(6S):8–158. (In Russ.) https://doi.org/10.18087/cardio.2475 (In Russ.)]
  6. McMurray J.J., Packer M., Desai A.S. et al. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371: 993–1004.
  7. EMA, New medicine to treat heart failure recommended for approval. Available at: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Public_assessment_ report/ human/004062/WC500197538.pdf.
  8. ESC GUIDELINES. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016; 18(8):891–975.
  9. FDA. FDA approves new drug to treat heart failure. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm453845.htm
  10. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O’Connor CM, Teerlink JR, Zannad F, Solomon SD. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail 2018;20:963–72.
  11. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380: 539–48.
  12. Kobalava Z.D., Villevalde S.V., Lukina O.I. A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the RARADIGM HF-Trial. Cardiology. 2017;2:76–82 (In Russ).
  13. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.
  14. Pfeffer MA, Swedberg K, Granger CB. CHARM Investigators and Committees. Effects of candesartanon mortality and morbidity in patients with chronic heart failure: the CHARMOverall programme. Lancet. 2003; 362:759–66.
  15. McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: CHARM-Added trial. Lancet. 2003; 362: 767–71.
  16. Kobalava Z.D., Villevalde S.V., Meray I.A., Lukina O.I. Effect of Sacubitril/Valsartan on Natriuresis, Diuresis and Blood Pressure in Hypertensive Patients. Rational Pharmacotherapy in Cardiology 2017;13(3):370–377. doi: 10.20996/1819–6446– 2017–13–3–370–377 (In Russ).]
  17. Kobalava Z.D., Villevalde S.V., Meray I.A., Shkolnikova E.E., Lukina O.I. Effects of sacubitril/valsartan on the arterial stiffness and left ventricular-arterial coupling in patients with heart failure with reduced ejection fraction. Rational Pharmacotherapy in Cardiology. 2018;14(2): 210–216
  18. Galochkin S.A., Lukina O.I., Meray I.A., Villevalde S.V., Kobalava Z.D. Experience of hospital initiation of sacubitril/ valsartan in a female patient after acute decompensated heart failure. Kardiologiia. 2018; 58(5S):60–64. (In Russ.) https://doi. org/10.18087/cardio.2477
  19. Watcher R. et al. Initiation of sacubitril/valsartan in haemodinamically stabilized heart failure patients in hospital or early after discharge: primary results of the randomized TRANSITION study. Eur J Heart Fail 2019. DOI: 10.1002/ ejhf.1498–15.

Copyright (c) 2020 Kobalava Z.D., Galochkin S.A., Tolkacheva V.V., Bagmanova N.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies